YuanBio Venture Capital
Overview
Yuanbio Venture Capital is a leading healthcare investment firm focusing on early and growth stage investment opportunities. Headquartered in Suzhou bioBay, they look for highly innovative companies across the country and keeps a global view on the development of healthcare industry . Till now, there are over 190 companies in their investment portfolio, covering biotech, medical devices, IVD and healthcare services, and 19 of the companies are listed on the SRAT Board, HKEX and Nasdaq, delivering outstanding performance to their funds . YuanBio has been awarded as one of the top healthcare VCs in China for many consecutive years .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| AusperBio | Aug 2026 | Series C | Co-investor |
| Beyang Therapeutics Co., Ltd. | Aug 2026 | Series A | Co-investor |
| CORE Biomedicine | Jul 2026 | Series A | Co-investor |
| Chengdu Zhenyu Biopharmaceutical Technology Co., Ltd. | May 2026 | Series A | Lead |
| Excalipoint Therapeutics | Mar 2026 | Seed | Lead |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is YuanBio Venture Capital based?
YuanBio Venture Capital is headquartered in Jiangsu.
When was YuanBio Venture Capital founded?
YuanBio Venture Capital was founded in 2013.
How many portfolio companies does YuanBio Venture Capital have?
YuanBio Venture Capital has 75 portfolio companies in Caplight's dataset.
What are some companies in YuanBio Venture Capital's portfolio?
Recent investments visible on Caplight include AusperBio, Beyang Therapeutics Co., Ltd., CORE Biomedicine, Chengdu Zhenyu Biopharmaceutical Technology Co., Ltd., Excalipoint Therapeutics.
What was YuanBio Venture Capital's most recent investment?
YuanBio Venture Capital's most recent investment on Caplight was in AusperBio in 2026.
What sectors does YuanBio Venture Capital focus on?
YuanBio Venture Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Consumer & Commerce, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Media, Entertainment & Gaming, Consumer & Commerce, Consumer & Commerce, Frontier & Industrial Tech, Enterprise Software, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Consumer & Commerce, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Consumer & Commerce, Frontier & Industrial Tech, Frontier & Industrial Tech, Enterprise Software, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Frontier & Industrial Tech, Enterprise Software.
What company stages does YuanBio Venture Capital focus on?
YuanBio Venture Capital typically invests at the Early stage.
What is YuanBio Venture Capital's AUM?
YuanBio Venture Capital's assets under management are estimated between $1.0B and $10.0B.